CHE

LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023

Retrieved on: 
Saturday, March 18, 2023
Managed Care, Pharmaceutical, Health, Clinical Trials, Janus, American Academy of Dermatology, American Academy, JAK, IGA, Leo Pharma, Patient, AAD, CHE, DELTA, Week, Safety, LEO, Pharmaceutical industry, Silviculture

The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.

Key Points: 
  • The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.
  • A significantly greater proportion of delgocitinib-treated patients, compared to cream vehicle, achieved this IGA-CHE improvement (19.7% vs. 9.9%; p=0.006).
  • A significantly greater proportion of delgocitinib-treated patients achieved a ≥75% improvement in Hand Eczema Severity Index (HECSI-75) compared to cream vehicle (49.2% vs. 23.5%; p
  • We are incredibly excited to share the positive results of this trial, which demonstrates the potential that delgocitinib cream has as a first-in-class innovative topical treatment.”

Bipartisan, Bicameral OFF Act to Address Corruption and Scandals at USDA Commodity Checkoff Programs Introduced in U.S. House and Senate

Retrieved on: 
Wednesday, March 1, 2023
Well, OCM, USDA, Congress, Grupo Lala, Food, OFF, National Taxpayers Union, CHE, Electoral History of the Conservative Party of New York State (U.S. House Results), Organization, Farmer, Egg, Fairness, AG, Work, Research, White meat, Legislation, Latin American Center for Human Economy, Culture, Dan Sullivan (U.S. senator), United States farm bill, Environment, National Farmers Union (United States), Senate, Government, Lobbying, National Farmers Union, Commodity, House, Movement, Competition, Animal, Competition (economics), Pork. The Other White Meat, AWA, Livestock, Pharmaceutical industry, Agriculture

“Farmers and Ranchers are being forced to pay into checkoff programs that often advocate against their best interest and support food system consolidation.

Key Points: 
  • “Farmers and Ranchers are being forced to pay into checkoff programs that often advocate against their best interest and support food system consolidation.
  • These programs need transparency and oversight so a farmer can be sure they aren’t required to fund their own demise,” said U.S.
  • Commodity checkoff programs (“checkoff programs”) were established to serve as mechanisms by which agricultural industries pool money for common commodity-specific promotional and research purposes.
  • Despite the limited purpose of the checkoffs, checkoff programs have repeatedly acted beyond the scope of their statutory mandate.

ASN002 (Gusacitinib) Emerging Drug Insight and Market 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 23, 2023
Health, Pharmaceutical, Janus, Clinical trial, HE, JAK, JAK3, News, SYK, B cell, JAK1, Research, United Kingdom, EU4, T helper 17 cell, Keratinocyte, CHE, T helper cell, Neutrophil, Book, Pancreatic serous cystadenoma, Macrophage, JAK2, TYK2, Cytokine, Lymphoma, Epithelium, SWOT, Fine chemical, Pharmaceutical industry, Vaccine, Hand eczema

The "ASN002 (Gusacitinib) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "ASN002 (Gusacitinib) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Further, it also consists of future market assessments inclusive of the ASN002 (Gusacitinib) market forecast, analysis for Hand Eczema in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hand Eczema.
  • Other emerging products for Hand Eczema (HE) are expected to give tough market competition to ASN002 (Gusacitinib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What is the clinical trial status of the study related to ASN002 (Gusacitinib) in Hand Eczema (HE) and study completion date?

LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 2 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE), Confirming the Positive Results of the Recent DELTA 1 Trial

Retrieved on: 
Friday, February 10, 2023
Health, Science, Pharmaceutical, Research, Clinical Trials, Janus, Leo Pharma, Delgocitinib, DELTA, CHE, Quality of life, Patient, LEO, JAK, Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 2 trial.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 2 trial.
  • DELTA 2 is the second of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
  • Further analyses of the data set will be conducted to determine the full potential of delgocitinib cream in the treatment of adults with moderate to severe CHE.
  • Detailed results from DELTA 2 are planned to be submitted for scientific presentation and publication at a later date.

LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 1 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE)

Retrieved on: 
Tuesday, December 6, 2022
Pharmaceutical, Health, Clinical Trials, Janus, Leo Pharma, Immune system, DELTA, Patient, Prevalence, Science, DKK, JAK, CHE, LEO, Research, Hyperkeratosis, Disease, Pain, Fissure, Quality of life, Erythema, Week, Itch, Hand eczema, HE, Skin, Safety, JT, Edema, Dermatology, Pharmaceutical industry, Silviculture

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 1 trial.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 1 trial.
  • DELTA 1 is the first of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
  • In addition to the DELTA 1 trial, delgocitinib cream is also being investigated in the second pivotal trial DELTA 2, which is still ongoing.
  • LEO Pharma is currently developing delgocitinib in a cream formulation for the treatment of moderate to severe chronic hand eczema (CHE) in adults.

TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio

Retrieved on: 
Tuesday, November 29, 2022
CHE, Itch, Dermatology, Sanofi, Sleep, Conditional sentence, Pain, Libertas, Patient, Workforce, Drug development, CNS, Depression, Asana, Quality of life, Rheumatology, Atopic dermatitis, Acquisition, Pharmaceutical industry

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- TrialSpark announced today the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences.

Key Points: 
  • NEW YORK, Nov. 29, 2022 /PRNewswire/ -- TrialSpark announced today the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences.
  • Libertas Bio will continue the development of these assets, leveraging TrialSpark's tech-enabled drug development capabilities to bring these therapies to patients faster and more efficiently.
  • After acquiring a portfolio of immunodermatology assets from Asana BioSciences, TrialSpark forms Libertas Bio.
  • Libertas Bio is open to in-licensing additional complementary products to build a differentiated pipeline focused on immunodermatology treatments.

Specialty Food Association Trendspotter Panel Predicts Top 2023 Specialty Food Trends

Retrieved on: 
Thursday, October 27, 2022
Seed, LLC, Cheese, Drink, Food, CFS, Specialty Food Association, Agriculture, CRC, Travel, Cleaner, Oil, Memory, Berbere, Cirkus, Industry, Drexel University, Association, Honey, Snack, Seafood, Awareness, Research, Taste, Fruit, Global Food Safety Initiative, Immunity, Seaweed, Doctor of Philosophy, Health, CHE, Vegetable, Condiment, Poultry, Restaurant, Hotel, Spice, Soft drink, SFA

NEW YORK, Oct. 27, 2022 /PRNewswire/ -- From Environmentally Friendly Foods to Alt Seafood and everything in between, the Specialty Food Association (SFA) Trendspotter Panel has predicted what will be hot in specialty food for 2023.

Key Points: 
  • NEW YORK, Oct. 27, 2022 /PRNewswire/ -- From Environmentally Friendly Foods to Alt Seafood and everything in between, the Specialty Food Association (SFA) Trendspotter Panel has predicted what will be hot in specialty food for 2023.
  • The largest B2B specialty food event in the western United States, the Winter Fancy Food Show features thousands of specialty food and beverage products from around the world.
  • The Specialty Food Association (SFA) has been the leading trade association and source of information about the $175 billion specialty food industry for 70 years.
  • The SFA is known for its Fancy Food Shows ; the sofi Awards , which have honored excellence in specialty food and beverage for 50 years; the Trendspotter Panel Show reports and annual predictions; the State of the Specialty Food Industry Report and Today's Specialty Food Consumer research; the SFA Product Marketplace , where buyers discover new products, network and connect with SFA members; SFA Feed , the daily source for industry news, trends and new product information, and Spill & Dish: A Specialty Food Association Podcast .

LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, Janus, Tralokinumab, Jake Virtanen, Systematic review, JT, Safety, Pain, Research, Atopic dermatitis, Ageing, Swelling, United Arab Emirates, BioDrugs, Disease, Itch, Autoimmune disease, JAAD, Diagnosis, Science, Poster, HE, Blister, DKK, Annual general meeting, European Academy of Allergy and Clinical Immunology, Immune system, Prevalence, CHE, Thyssen, Adult, AD, Epidemiology, Congress, JAK, Leo Pharma, Journal of the European Academy of Dermatology and Venereology, Patient, Vaccine, Pharmaceutical industry, Medical device, Hospital, Venereology, EU, Veni, vidi, vici, Dermatology

LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.

Key Points: 
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
  • 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis.
  • Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
  • Safety of tralokinumab in paediatric patients aged 12-17 with moderate-to-severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial.

Mukteshwari "Mukti" Bosco Receives 2022 Roux Prize

Retrieved on: 
Friday, July 22, 2022
Indian Institute of Science, University of Washington School of Medicine, University, Health education, Woman, CEO, Institute for Health Metrics and Evaluation, Research, Disease, Population health, Health, Institute, Tata Institute of Social Sciences, Income, Deloitte, University of Washington Department of Global Health, Volunteering, Multimedia, Organization, Leadership, Government, Empowerment, Social science, CHE, IHME, Degenerative disease, Founder, Population, Health policy, Pharmaceutical industry, Medicine

SEATTLE, July 22, 2022 /PRNewswire/ -- The Institute for Health Metrics and Evaluation (IHME) at the University of Washington today announced Mukteshwari "Mukti" Bosco, CEO and Founder of Healing Fields Foundation, is the recipient of the 2022 Roux Prize, the world's largest award for evidence-based public health achievement. The annual award, sponsored by IHME's founding board member David Roux and his wife, Barbara, recognizes people worldwide for their innovative and impactful use of IHME's Global Burden of Disease data.

Key Points: 
  • SEATTLE, July 22, 2022 /PRNewswire/ -- The Institute for Health Metrics and Evaluation (IHME) at the University of Washington today announced Mukteshwari "Mukti" Bosco, CEO and Founder of Healing Fields Foundation , is the recipient of the 2022 Roux Prize, the world's largest award for evidence-based public health achievement.
  • "The Roux Prize recognizes creative problem-solvers like Mukti who are the driving force behind real change.
  • Her determination to overcome daunting barriers and turn evidence into action exemplifies the spirit of the Roux Prize."
  • "Receiving the Roux Prize reflects the transformative power of our Community Health Entrepreneurs, their communities, and the entire Healing Fields organization," said Bosco.

Next Generation 911 Markets: The Future of Public Safety - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 2, 2022
Public Policy, Government, Telecommunications, Construction & Property, Internet, Law Enforcement, Emergency Services, Technology, Urban Planning, Homeland Security, CHE, GIS, Geographic information system, Artificial intelligence, City, PSAP, Ecosystem, Solution, Intelligence, IOT, Call, Machine learning, Incidence, Industry, Information system, Internet of things, Management, Mobile phone

The "Next Generation 911: The Future of Public Safety - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next Generation 911: The Future of Public Safety - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • NG911 represents an industry transformation that proactively enhances public safety by acknowledging and catering to the rapidly evolving demands, products, lifestyles, and technologies of citizens.
  • Machine Learning (ML) and artificial intelligence (AI) solutions will be critical to manage, organize, and analyze the massive amounts of new data sources now enabled with NG911.
  • The ability to determine "what is relevant" versus "what is noise" in the context of an emergency event will be essential in order to optimize outcomes.